← Calendar
Readoutin 45d
Hoffmann-La Roche — Afimkibart
Phase 3 primary completion: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Moderately to Severely Active Ulcerative Colitis
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Hoffmann-La Roche
Mar2027
Readoutin 104d
Hoffmann-La Roche — AtezolizumabPhase 3 primary completion: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy.
Feb2027
Readoutin 76d
Hoffmann-La Roche — RanibizumabPhase 3 primary completion: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome).